FY2025 EPS Estimates for Globus Medical Raised by Analyst

Globus Medical, Inc. (NYSE:GMED) – Zacks Research increased their FY2025 EPS estimates for shares of Globus Medical in a report issued on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical device company will earn $3.43 per share for the year, up from their previous forecast of $3.42. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $0.97 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. The company had revenue of $625.71 million for the quarter, compared to the consensus estimate of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The firm’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same period last year, the firm earned $0.57 EPS.

A number of other brokerages have also recently commented on GMED. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $83.00 to $100.00 in a report on Monday, December 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research report on Thursday, January 9th. Stifel Nicolaus raised their target price on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. BTIG Research lifted their price target on Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Finally, Wells Fargo & Company increased their price target on Globus Medical from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $96.91.

Globus Medical Stock Up 0.4 %

Globus Medical stock opened at $92.82 on Thursday. Globus Medical has a 52 week low of $49.33 and a 52 week high of $93.67. The firm has a market cap of $12.64 billion, a price-to-earnings ratio of 138.53, a price-to-earnings-growth ratio of 1.78 and a beta of 1.19. The business’s 50-day moving average price is $84.87 and its 200 day moving average price is $76.56.

Insider Activity at Globus Medical

In other news, CEO Daniel T. Scavilla sold 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total value of $4,801,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kelly Huller sold 5,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total value of $405,050.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,667 shares of company stock valued at $6,674,554. 18.54% of the stock is owned by insiders.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Select Equity Group L.P. acquired a new position in shares of Globus Medical during the 2nd quarter valued at about $91,711,000. Millennium Management LLC boosted its holdings in Globus Medical by 1,171.5% in the 2nd quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock valued at $93,409,000 after purchasing an additional 1,256,570 shares during the last quarter. ArrowMark Colorado Holdings LLC purchased a new stake in shares of Globus Medical in the 3rd quarter valued at approximately $43,947,000. Lord Abbett & CO. LLC acquired a new stake in shares of Globus Medical during the 3rd quarter worth approximately $37,948,000. Finally, Parsifal Capital Management LP raised its position in shares of Globus Medical by 50.5% during the 3rd quarter. Parsifal Capital Management LP now owns 1,350,553 shares of the medical device company’s stock valued at $96,619,000 after buying an additional 453,053 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.